openPR Logo
Press release

Global Biosimilars Market Regulations & Pipeline Insight

06-29-2017 12:00 PM CET | Health & Medicine

Press release from: Kuick Resarch

Global Biosimilars Market Regulations & Pipeline Insight

The evolution of biosimilars has currently reached different stages across the world. Owing to variable clarity in the guidelines and diverse regulatory pathways, various definitions of biosimilars (or the broader group of follow-on biologics) have emerged across countries. Till now the European region has the best-established framework for biosimilars. The US is currently almost aligned to the European standards. Biosimilars are also known as follow on biologics in the US and subsequent entry biologics in Canada, are biologic products which are approved in a country, which has an abbreviated approval process for biologic products which references an originator biologic in the regulatory submission.

The global biosimilars market is categorized into monoclonal antibody biosimilars (mAbs), insulins, interferons, erythropoetins, filgrastim, somatropin and follicle stimulating hormone (FSH). Among the segments of the biosimilars market, the monoclonal antibodies (mAbs) and insulin market would witness maximum growth, with these two segments accounting for a dominant share of more than 40% of the total global biosimilars market by 2018. Additionally, with the mAbs having one of the strongest R&D pipeline in the biologics market, it is expected that many new next-generation technologies which would push mAb therapeutics into newer areas such as solid tumours, cardiovascular and neurological disorders would be introduced into the market.

Download Report:

https://www.kuickresearch.com/report-Global-Biosimilars-Market-Regulations-&-Pipeline-Insight.php

In terms of innovation in the biosimilars, it is most likely that the future market would witness the introduction of follitropins, interferons and low molecular weight heparins products, in addition to mAbs. Also, it is expected that some pharmaceutical companies could increasingly start focusing on specific therapeutic classes based on their capacity to manufacture and their strategic fit.

Almost all the countries across the globe are currently experiencing an increase in their ageing population with a parallel increase in the incidence of chronic diseases. However, an increase in the demand for high quality healthcare is generally associated with the issue of controlling spiraling healthcare expenditure. With the regulated and streamlined introduction of biosimilars into the market, it is most likely that there would be an increase in the accessibility and affordability of the much in demand biologic medicines. The next few years are likely to witness a new set of complex biosimilars products being developed owing to a significant number of leading brands of biologic drugs losing their patents by 2020.

“Global Biosimilars Market Regulations & Pipeline Insight 2014” Report Highlights:

* Market Overview
* Detailed Regulatory Pathways For 12 Countries/Regions
* Global Biosimilars Pipeline by Phase, Indication, Company & Country
* Biosimilars Pipeline: 276 in Development Phase
* Majority Biosimilars in Preclinical Phase: 76 Biosimilars
* Marketed Biosimilars by Indication, Company & Country: 113 Biosimilars

For Report Sample Contact: neeraj@kuickresearch.com or

visit: https://www.kuickresearch.com

Recent Publications:

* Global Cancer Immunotherapy Market & Clinical Trials Outlook 2022
* Global CAR T Cell Therapy Market & Clinical Trials Insight 2022
* Global Dendritic Cell Cancer Vaccine Market & Clinical Trials Outlook 2023
* Global Microcapsules Drug Delivery Market Opportunity Outlook 2022
* Global Controlled Drug Delivery Market & Clinical Trial Outlook 2022
* Global Cancer Antibody Drug Conjugates Market & Pipeline Insight 2022
* Global B Cell Lymphoma Market & Clinical Pipeline Insight 2022

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Biosimilars Market Regulations & Pipeline Insight here

News-ID: 601515 • Views: 166

More Releases from Kuick Resarch

Global Orphan Drug Rare Disease Market Clinical Trials Forecast 2028
Global Orphan Drugs Clinical Trials Insight Report Highlights: • Clinical Insight On More Than 400 Marketed Orphan Drugs • Clinical Insight On More Than 1300 Orphan Drugs in Clinical Trials • Orphan Designated Drug Clinical Status by Indication & Country • Global Market Opportunity More Than USD 350 Billion • Market Exclusivity & Patent Protection Criteria for Orphan Drugs • Global & Regional Orphan Drug Market Sales Opportunity • Orphan Drug Reimbursement Policy • Orphan Clinical Pipeline Overview
Global CD233 Antibody Market Clinical Trials Intelligence 2028
Global CD233 Inhibitors Trials Intelligence Report Highlights: • Global CD233 Inhibitors Market Dynamics • Clinical Approaches to Target CD233 Inhibitors • Role of CD233 Inhibitors in Cancer, Autoimmune Disorders • Number of CD233 Inhibitors Drug In Trials • CD233 Inhibitors Approved Patent Insight • CD233 Inhibitors Trials By Phase, Company, Country, Indication • Company Agreement/Partnership/Deals For Ongoing Trials • Global CD233 Inhibitor Market Future Outlook For Report Sample Contact neeraj@kuickresearch.com The successful application of the anti-CTLA-4 and anti-PD-1/PD-L1
Global Gene Therapy Market Clinical Trials Research Insight 2028
Global Gene Therapy Market & Clinical Trials Intelligence Report Highlights • Global Market Gene Therapy Landscape USD 24 Billion Opportunity • Comprehensive Commercial & Clinical insight on 16 Approved Gene Therapies • Gene Therapy Products Dosage & Price Analysis • Comprehensive Clinical Insight On 1700 Gene Therapies In Clinical Trials • Information On 45 Orphan Designated Gene Therapies By Indication, Country, Company • Global Gene Therapy Clinical Trials Insight By Phase, Country, Formulations, Company, Indication, Target •
TROP2 Targeted Therapy Trodelvy Market Clinical Trials Insight 2026
Global TROP2 Antibody Market & Clinical Trials Insight 2026 Report Analysis and Data Highlights: • Research Methodology • Global & Regional Market Analysis • Global TROP2 Antibody Market Opportunity Assessment: > USD 4 Billion • Market and Drug Sales Insight 2020 Till 2026 • Approved Drug In Market: 1 Drugs • Approved TROP2 Antibody Patent, Price and Sales insight 2020 Till 2026 • Future Market Assessment By Indication Till 2026 • Ongoing Clinical Trials Assessment by Status, Phase & Region • Key Market Dynamics • Competitor Landscape Download Report:

All 5 Releases


More Releases for Biosimilars

Global Oncology Biosimilars Market | Global Oncology Biosimilars Industry | Onco …
The oncology biosimilars market involves of sales of medicine and drug interrelated products for cancer treatment. Biosimilars are pharmaceuticals which are produced using cell lines and are fashionable to the manufacturer. The manufacturing of such cell line processes is a multipart and time-consuming procedure. According to the report analysis, ‘Oncology Biosimilars Market Global Report 2020-30’ states that the worldwide oncology biosimilars market was worth USD 2990.34 million in 2019. It is
Global Biosimilars Market | Global Biosimilars Industry | Global Biosimilars Mar …
The biosimilars market involves of sales of biosimilars and associated services that are cast-off to treat chronic sicknesses such as diabetes, arthritis, and cancer. The Biosimilars are pharmaceuticals that are produced using cell lines and offers no clinical difference as linked to biologics. The Biosimilars are made once the patent of biologics is deceased. According to the report analysis, ‘Biosimilars Market Global Report 2020-30’ states that the worldwide biosimilars market was
Global Biosimilars Market Research Report
This report studies the global Biosimilars market status and forecast, categorizes the global Biosimilars market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report Pfizer Sandoz International GmbH Teva Pharmaceuticals Industries Amgen Inc Biocon Dr. Reddy’s Laboratories F. Hoffmann-La Roche Celltrion Samsung Bioepis
Insulin Biosimilars Market, by Biosimilar Type Rapid-acting Biosimilars, Long-ac …
Diabetes is a group of metabolic disease characterized by high blood sugar level due to inadequate secretion of insulin. Common symptoms of diabetes include increased hunger, tiredness, weight loss, and excessive thirst and urination. The prevalence of diabetes is increasing, in turn, boosting demand for insulin biosimilar. For instance, according the World Health Organization (WHO) report in 2014, globally around 422 million adults were living with diabetes and 1.5 million
Insulin Biosimilars Market, by Biosimilar Type Rapid-acting Biosimilars, Long-ac …
Biosimilar is a medicine developed on the original biological reference product. The production process of biopharmaceuticals vary from one manufacturer to another, thus every biosimilar product is unique from the other. Biosimilar manufactures use different culture conditions, master cell lines, purification techniques, and raw materials. This in turn, helps meet the rising prevalence of diabetes due to inadequate healthcare services, rising prevalence of obesity, For instance, According to 2013 American
Enbrel Biosimilars Clinical Trial Insight
“Enbrel Biosimilars Clinical Trial Insight” report by PNS Pharma gives comprehensive clinical insight on 36 biosimilars version of Enbrel drug in clinical pipeline. More than 5 of these biosimilars are in Phase-III trials and are expected to be commercially available in next 5-8 years. Currently 5 biosimilar version of Enbrel are commercially available in Iran, Mexico, India, UK and Australia. The patent on Enbrel was originally set to expire on